Skip to main content
Vaxil Bio Ltd. logo

Vaxil Bio Ltd. — Investor Relations & Filings

Ticker · VXL TSXV Professional, scientific and technical activities
Open in API
Filings indexed 116 across all filing types
Latest filing 2025-12-04 Capital/Financing Update
Country CA Canada
Listing TSXV VXL

About Vaxil Bio Ltd.

http://vaxil-bio.com

Vaxil Bio Ltd. is a biotechnology company focused on developing novel immunotherapies and targeted therapies. The company utilizes a proprietary drug discovery and development platform centered on Signal Peptides (SPs). This platform leverages signal peptide domains found on specific proteins to create targeted treatments. Vaxil's pipeline includes neoantigen-like peptide products and antibodies designed to address significant unmet medical needs in both cancer (immuno-oncology) and infectious diseases.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release covering two primary events: the completion of a private placement financing (capital raising) and changes to the Board of Directors (resignations and a new appointment). While it contains management information, the primary financial event is the closing of a private placement, which falls under 'Capital/Financing Update' (CAP). Given the dual nature, CAP is the most specific category for the financing activity described.
2025-12-04 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non-brokered private placement of units (shares and warrants) to raise capital. It details the offering price, the use of proceeds, and the conditions for closing. This falls directly under the definition of a capital/financing update.
2025-11-24 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non-brokered private placement of shares and warrants to raise gross proceeds of up to $350,000. It details the terms of the offering, conditions for closing, use of proceeds, and related finders’ fees. This is a clear announcement of a fundraising activity and a change in capital structure, matching the definition for a Capital/Financing Update (CAP).
2025-10-29 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three-month period ended March 31, 2025.” It is the standalone MD&A narrative discussing Q1 results, trends, liquidity, capital resources and forward-looking statements, rather than a brief press release or the full interim financial statements. This matches the Management Reports category (Code: MDA).
2025-05-27 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a “FORM 52-109FV2” certification by the CFO of Vaxil Bio Ltd. for interim filings under Canadian NI 52-109. It is not the interim financial report (IR category) itself but a statutory certificate accompanying the filings. It does not announce publication nor provide executive summaries; rather, it is a compliance filing under securities legislation. It does not fit any specific category (e.g., earnings release, MD&A, dividend notice) and thus falls into the general regulatory filings fallback.
2025-05-27 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a statutory certificate (Form 52-109FV2) certifying the review and fair presentation of interim financial statements and MD&A for the period ended March 31, 2025. It is not the interim report itself (IR) nor an announcement of publication (RPA). It represents a regulatory submission under NI 52-109. Therefore, it best fits the fallback Regulatory Filings category (RNS).
2025-05-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.